Ygion Biomedical develops individualized neoantigen-based cancer vaccines using a proprietary suite of technologies to identify, produce and target delivery of relevant peptide neoepitopes. Its YGNITE™ platform combines sequencing, bioinformatics and the proprietary CARGONAUT™ vaccine platform to deliver neoepitope peptide vaccines tailored to each tumor and patient. The company positions its approach as a "plug-and-play" system for precise, targeted activation of the patient immune system. YG-01 is the lead program and is currently in preclinical development. Ygion is led by CEO Dr. Wolfgang Fischl and CTO Dr. Geert Mudde. The company intends to advance YG-01 into preclinical and clinical development using newly raised funds.

Total raised

$16M

Funding rounds

1

Latest round

Series A

Latest activity

May 2024